185 related articles for article (PubMed ID: 37595040)
1. FOXA1 O-GlcNAcylation-mediated transcriptional switch governs metastasis capacity in breast cancer.
Liu Y; Yu K; Kong X; Zhang K; Wang L; Zhang N; Chen Q; Niu M; Li W; Zhong X; Wu S; Zhang J; Liu Y
Sci Adv; 2023 Aug; 9(33):eadg7112. PubMed ID: 37595040
[TBL] [Abstract][Full Text] [Related]
2. FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer.
Fu X; Pereira R; De Angelis C; Veeraraghavan J; Nanda S; Qin L; Cataldo ML; Sethunath V; Mehravaran S; Gutierrez C; Chamness GC; Feng Q; O'Malley BW; Selenica P; Weigelt B; Reis-Filho JS; Cohen O; Wagle N; Nardone A; Jeselsohn R; Brown M; Rimawi MF; Osborne CK; Schiff R
Proc Natl Acad Sci U S A; 2019 Dec; 116(52):26823-26834. PubMed ID: 31826955
[TBL] [Abstract][Full Text] [Related]
3. Resistance to bortezomib in breast cancer cells that downregulate Bim through FOXA1 O-GlcNAcylation.
Liu Y; Wang X; Zhu T; Zhang N; Wang L; Huang T; Cao Y; Li W; Zhang J
J Cell Physiol; 2019 Aug; 234(10):17527-17537. PubMed ID: 30793308
[TBL] [Abstract][Full Text] [Related]
4. O-GlcNAcylation affects β-catenin and E-cadherin expression, cell motility and tumorigenicity of colorectal cancer.
Harosh-Davidovich SB; Khalaila I
Exp Cell Res; 2018 Mar; 364(1):42-49. PubMed ID: 29391154
[TBL] [Abstract][Full Text] [Related]
5. Chromatin-associated OGT promotes the malignant progression of hepatocellular carcinoma by activating ZNF263.
Wang L; Li G; Zhou Z; Ge C; Chen Q; Liu Y; Zhang N; Zhang K; Niu M; Li W; Zhong X; Wu S; Zhang J; Liu Y
Oncogene; 2023 Jul; 42(30):2329-2346. PubMed ID: 37353617
[TBL] [Abstract][Full Text] [Related]
6. O-GlcNAcylation in cancer development and immunotherapy.
He XF; Hu X; Wen GJ; Wang Z; Lin WJ
Cancer Lett; 2023 Jul; 566():216258. PubMed ID: 37279852
[TBL] [Abstract][Full Text] [Related]
7. O-GlcNAcylation regulates breast cancer metastasis via SIRT1 modulation of FOXM1 pathway.
Ferrer CM; Lu TY; Bacigalupa ZA; Katsetos CD; Sinclair DA; Reginato MJ
Oncogene; 2017 Jan; 36(4):559-569. PubMed ID: 27345396
[TBL] [Abstract][Full Text] [Related]
8. High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer.
Fu X; Pereira R; Liu CC; De Angelis C; Shea MJ; Nanda S; Qin L; Mitchell T; Cataldo ML; Veeraraghavan J; Sethunath V; Giuliano M; Gutierrez C; Győrffy B; Trivedi MV; Cohen O; Wagle N; Nardone A; Jeselsohn R; Rimawi MF; Osborne CK; Schiff R
Cell Rep; 2023 Aug; 42(8):112821. PubMed ID: 37467106
[TBL] [Abstract][Full Text] [Related]
9. Suppression of OGT by microRNA24 reduces FOXA1 stability and prevents breast cancer cells invasion.
Liu Y; Huang H; Cao Y; Wu Q; Li W; Zhang J
Biochem Biophys Res Commun; 2017 Jun; 487(3):755-762. PubMed ID: 28455227
[TBL] [Abstract][Full Text] [Related]
10. Twist1 promotes breast cancer invasion and metastasis by silencing Foxa1 expression.
Xu Y; Qin L; Sun T; Wu H; He T; Yang Z; Mo Q; Liao L; Xu J
Oncogene; 2017 Feb; 36(8):1157-1166. PubMed ID: 27524420
[TBL] [Abstract][Full Text] [Related]
11. O-GlcNAcylation of cofilin promotes breast cancer cell invasion.
Huang X; Pan Q; Sun D; Chen W; Shen A; Huang M; Ding J; Geng M
J Biol Chem; 2013 Dec; 288(51):36418-25. PubMed ID: 24214978
[TBL] [Abstract][Full Text] [Related]
12. mTOR/MYC Axis Regulates O-GlcNAc Transferase Expression and O-GlcNAcylation in Breast Cancer.
Sodi VL; Khaku S; Krutilina R; Schwab LP; Vocadlo DJ; Seagroves TN; Reginato MJ
Mol Cancer Res; 2015 May; 13(5):923-33. PubMed ID: 25636967
[TBL] [Abstract][Full Text] [Related]
13. O-GlcNAcylation of MEK2 promotes the proliferation and migration of breast cancer cells.
Xu Y; Sheng X; Zhao T; Zhang L; Ruan Y; Lu H
Glycobiology; 2021 Jun; 31(5):571-581. PubMed ID: 33226073
[TBL] [Abstract][Full Text] [Related]
14. O-GlcNAcylation promotes topoisomerase IIα catalytic activity in breast cancer chemoresistance.
Liu Y; Yu K; Zhang K; Niu M; Chen Q; Liu Y; Wang L; Zhang N; Li W; Zhong X; Li G; Wu S; Zhang J; Liu Y
EMBO Rep; 2023 Jul; 24(7):e56458. PubMed ID: 37249035
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic switch involved in activation of pioneer factor FOXA1-dependent enhancers.
Sérandour AA; Avner S; Percevault F; Demay F; Bizot M; Lucchetti-Miganeh C; Barloy-Hubler F; Brown M; Lupien M; Métivier R; Salbert G; Eeckhoute J
Genome Res; 2011 Apr; 21(4):555-65. PubMed ID: 21233399
[TBL] [Abstract][Full Text] [Related]
16. O-GlcNAcylation of MORC2 at threonine 556 by OGT couples TGF-β signaling to breast cancer progression.
Liu YY; Liu HY; Yu TJ; Lu Q; Zhang FL; Liu GY; Shao ZM; Li DQ
Cell Death Differ; 2022 Apr; 29(4):861-873. PubMed ID: 34974534
[TBL] [Abstract][Full Text] [Related]
17. FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer.
Arruabarrena-Aristorena A; Maag JLV; Kittane S; Cai Y; Karthaus WR; Ladewig E; Park J; Kannan S; Ferrando L; Cocco E; Ho SY; Tan DS; Sallaku M; Wu F; Acevedo B; Selenica P; Ross DS; Witkin M; Sawyers CL; Reis-Filho JS; Verma CS; Jauch R; Koche R; Baselga J; Razavi P; Toska E; Scaltriti M
Cancer Cell; 2020 Oct; 38(4):534-550.e9. PubMed ID: 32888433
[TBL] [Abstract][Full Text] [Related]
18. Hyper-
Ma Z; Chalkley RJ; Vosseller K
J Biol Chem; 2017 Jun; 292(22):9150-9163. PubMed ID: 28416608
[No Abstract] [Full Text] [Related]
19. Undetectable histone O-GlcNAcylation in mammalian cells.
Gagnon J; Daou S; Zamorano N; Iannantuono NV; Hammond-Martel I; Mashtalir N; Bonneil E; Wurtele H; Thibault P; Affar el B
Epigenetics; 2015; 10(8):677-91. PubMed ID: 26075789
[TBL] [Abstract][Full Text] [Related]
20.
Liu L; Li L; Ma C; Shi Y; Liu C; Xiao Z; Zhang Y; Tian F; Gao Y; Zhang J; Ying W; Wang PG; Zhang L
J Biol Chem; 2019 Nov; 294(45):16620-16633. PubMed ID: 31527085
[No Abstract] [Full Text] [Related]
[Next] [New Search]
